Evidence map›Paper›PMID 26124671›Full record

ArticleOncoTargets and therapy2015

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis.

Meiling Lu, Jinghua Li, Zaili Luo, Shuai Zhang, Shaobo Xue, Kesheng Wang, Yan Shi, Cunzhen Zhang, Haiyang Chen, Zhong Li

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Targeting Prostate Cancer, the 'Tousled Way'.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Meiling LuCentral Laboratory, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Jinghua LiCentral Laboratory, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Zaili LuoInternational Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute/Hospital, The Second Military Medical University, Shanghai, People's Republic of China ; Institution of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China.
Shuai ZhangInstitution of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China.
Shaobo XueCentral Laboratory, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Kesheng WangCentral Laboratory, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Yan ShiDepartment of Gastroenterology, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Cunzhen ZhangInstitution of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China.
Haiyang ChenInstitution of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China.
Zhong LiCentral Laboratory, The 10th People's Hospital, Tongji University, Shanghai, People's Republic of China ; Zhangjiang Center for Translational Medicine, Shanghai, People's Republic of China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor metastasis is the most common cause of death and poor prognosis for cancer patients. Therapeutics that prevent tumor metastasis are the key to prolonging the lifespan of cancer patients. Cancer stem cells are believed to be critical in the metastatic process. Recently, drug screening for cancer stem cells reports that antipsychotic drugs displayed potential anticancer activity. Thioridazine, one of the antipsychotic drugs for dopamine receptors (DRs), is shown to induce the differentiation of cancer stem cells in leukemic disease and breast cancer, but it is not known if this drug would affect liver cancer. In this study, expression of DR5 was higher in tumors than in nontumor adjacent tissues, while DR1 was lower in human hepatocellular carcinoma (HCC) than those in the adjacent tissues. Other DRs were very low or undetectable. Treatment of HCC cells with thioridazine displays a dose-dependent response in HCC cell lines SNU449, LM3, and Huh7. Thioridazine treatment reduced cell viability and sphere formation of HCC cell lines through induction of G0/G1 cell cycle arrest and suppression of stemness genes CD133, OCT4, and EpCam. It also inhibited cell migration via suppression of epithelial-mesenchymal transition (EMT)-related genes such as twist2 and E-cadherin. Thioridazine-pretreated LM3 cells decreased the capacity of tumorigenesis in nude mice. Taken together, our data suggest that thioridazine may have the potential role in treatment of HCC.

Indexed as

antipsychoticdopamine receptorsHCCmetastasisthioridazine

Identifiers

PMID26124671
PMCPMC4482370
OpenAlexW1648152516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.